EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Resmetirom attenuates atherosclerosis-associated dyslipidemia and vascular inflammation in high-fat diet-fed ApoE−/− mice

Xuedong Bai iD, Wenjie Fei, Jingzhou Fang, Chaomin Kong, Yaqi Xiang, Yuele Tian, Limin Wei

PLOS One · 2026

DOI: 10.1371/journal.pone.0359161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Xuedong Bai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Diet, High-Fat, Atherosclerosis, Dyslipidemias, Apolipoproteins E. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hebei Province Medical Science Research Project Plan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atherosclerosis is driven by interacting lipid and inflammatory pathways. There remains a pressing clinical need for drugs that exert both lipid-lowering and vascular anti-inflammatory effects. Studies have suggested that thyroid hormone receptor β (THR-β) agonists can alleviate atherosclerosis while avoiding the cardiotoxic adverse effects associated with thyroid hormone. Resmetirom is an oral, once-daily, liver-targeted selective THR-β agonist. It has attracted attention for improving lipid metabolism, yet its effects on vascular inflammatory phenotypes remain poorly clarified. We investigated the effects of resmetirom on atherosclerosis-associated dyslipidemia, plaque burden and vascular inflammatory phenotypes.

Methods

Apolipoprotein E-deficient (ApoE - / - ) mice fed a high-fat diet (HFD) for 8 weeks were randomized to vehicle, low-dose (3 mg/kg/day), or high-dose (10 mg/kg/day) resmetirom for eight weeks ( n = 10 per group). Serum lipids, inflammatory cytokines, aortic plaque morphology, NLRP3 inflammasome signaling, NF-κB activation, oxidative stress, and macrophage polarization were analyzed by one-way ANOVA with Tukey post hoc testing; dose-response regression was performed across disease-bearing groups.

Results

Resmetirom treatment reduced aortic plaque burden, corrected atherogenic dyslipidemia, and suppressed aortic NLRP3 and caspase-1 expression in a dose-dependent manner. High-dose resmetirom lowered low-density lipoprotein cholesterol (LDL-C) by 39.48%, and reduced aortic lipid accumulation on Oil Red O staining compared to model controls. Additionally, it suppressed interleukin-1β (IL-1β) by 59.28%; Western blotting showed lower p-p65/total p65 ratio and higher IκBα/GAPDH abundance. Flow-cytometric ROS intensity decreased by 35.56%, and the M1/M2 macrophage ratio decreased by 72.81%. Exploratory cross-assay analyses showed coherent associations among systemic cytokines and aortic NF-κB/ROS/macrophage readouts.

Conclusions

Resmetirom attenuated atherosclerosis-associated dyslipidemia, plaque burden and vascular inflammation in HFD ApoE −/− mice. The data support an association between resmetirom treatment and suppression of the NF-κB/ROS-NLRP3 inflammatory phenotype, warranting mechanistic validation in models with direct pathway perturbation. These findings support its translational potential in atherosclerotic cardiovascular disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diet, High-FatAtherosclerosisDyslipidemiasApolipoproteins EVasculitisAnimalsMiceMaleNF-kappa BOxidative StressNLR Family, Pyrin Domain-Containing 3 ProteinInflammationCytokinesMice, Inbred C57BLMice, Knockout

Substanzen

Apolipoproteins ENF-kappa BNLR Family, Pyrin Domain-Containing 3 ProteinCytokines

Autor:innen und Institutionen

  • Department of Internal Medicine, Hebei Medical University, Shijiazhuang, Hebei, China.
  • Department of Geriatric Cardiology, Hebei General Hospital, Shijiazhuang, Hebei, China.
  • Department of Endocrinology, Hebei General Hospital, Shijiazhuang, Hebei, China.
  • Department of Endocrinology, Langfang People's Hospital, Langfang, Hebei, China.

ORCID-Profile: Xuedong Bai

Förderung

  • Hebei Province Medical Science Research Project Plan

Zitieren

APA

Bai, X., Fei, W., Fang, J., Kong, C., Xiang, Y., Tian, Y., & Wei, L. (2026). Resmetirom attenuates atherosclerosis-associated dyslipidemia and vascular inflammation in high-fat diet-fed ApoE−/− mice. PLOS One. https://doi.org/10.1371/journal.pone.0359161

Vancouver

Bai X, Fei W, Fang J, Kong C, Xiang Y, Tian Y, et al. Resmetirom attenuates atherosclerosis-associated dyslipidemia and vascular inflammation in high-fat diet-fed ApoE−/− mice. PLOS One. 2026. doi:10.1371/journal.pone.0359161

BibTeX
@article{Bai2026,
  author = {Bai, Xuedong and Fei, Wenjie and Fang, Jingzhou and Kong, Chaomin and Xiang, Yaqi and Tian, Yuele and Wei, Limin},
  title = {Resmetirom attenuates atherosclerosis-associated dyslipidemia and vascular inflammation in high-fat diet-fed ApoE−/− mice},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0359161}
}
Kostenlos starten →